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Fibrocytes are a precursor cell type, which can differentiate into fibroblasts or adipocytes (1). 
The mesentery in Crohn’s disease, frequently displays disease manifestations such as 
mesenteric thickening and fat wrapping. This study aimed to investigate the contribution of 
fibrocytes to mesenteric manifestations in Crohn’s disease.  
Ethical approval and informed consent were obtained from the HSE Mid-Western 
Regional Hospital Research Ethics Committee. Mesenteric disease was graded based on 
presence and extent of factors listed in Table 1. Circulating and mesenteric fibrocytes were 
identified and enumerated by flow cytometric and immunohistochemical analysis. 
Relationships between these mesenteric and systemic manifestations were determined. Data 
are presented as mean ± standard error. Statistical analyses were performed in SPSSv22.  
Circulating fibrocytes were significantly elevated in Crohn’s disease (n=25) when 
compared to healthy controls (n=11) (independent t-test: 7.7 ± 0.97% vs. 2.1 ± 0.34%; 
p<0.001). Furthermore, Crohn’s disease mesentery displayed a higher number of 
myofibrocytes than normal tissue. Mesenteric disease activity index directly correlated with 
the systemic disease manifestations (Pearson’s correlation coefficient: r=0.80; p<0.05).  
The increase in fibrocytes is directly related to the extent of mesenteric disease.  
 
Table 1: Scoring system for mesenteric disease manifestations.  
Mesenteric Disease Activity Index 
Description Severity Grade Stage Score 
FW minimal, MT minimal Early Mild One 1 
FW <25%, MT adipovascular pedicle only Intermediate I Moderate Two A 2 
FW <25%, pan-mesenteric MT Intermediate II Moderate Two B 4 
FW >25%, pan-mesenteric MT Advanced Severe Three 6 
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